A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Part of paid clinical trials in Torrance, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT04875195
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — BIOLOGICAL
    Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.

Study Details

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

Key Dates

Start date
Jun 7, 2021
Status verified
Oct 2025
Primary completion
Dec 14, 2023
Completion
Oct 13, 2025

Study Design

Enrollment
66 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm 1
    Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.

Primary Outcome Measure

Objective Response Rate (ORR) Per Lugano Classification as Assessed by Investigator [ Time Frame: Up to approximately 30 months ]

Locations (3)

FacilityCityStateZIPSite coordinators
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( SiteTorranceCalifornia90502-
Tulane Medical Center ( Site 0110)New OrleansLouisiana70112-
Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)AnnapolisMaryland21401-

Related coverage on Hipa.ai

Find similar trials in Torrance, CA

By research site
Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site· Torrance, CATulane Medical Center· New Orleans, LAAnne Arundel Medical Center-Anne Arundel Oncology and Hematology· Annapolis, MD

Related Studies